Diferencia entre revisiones de «Angiotensin II»
(Switch SMW query from broadtable to table format for better layout with TOC) |
|||
| (No se muestran 4 ediciones intermedias de 2 usuarios) | |||
| Línea 30: | Línea 30: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* | *Thrombosis (13%) | ||
**DVT (4%) | **[[DVT]] (4%) | ||
*Thrombocytopenia (9%) | *Thrombocytopenia (9%) | ||
*Tachycardia (8.6%) | *Tachycardia (8.6%) | ||
| Línea 44: | Línea 44: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Synthetic human angiotensin II which is a peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure | *Synthetic human angiotensin II which is a peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure | ||
*Increases | *Increases Aldosterone | ||
==Comments== | ==Comments== | ||
*Patient's on ACEi may have increased response to Angiotensin II | *Patient's on ACEi may have increased response to Angiotensin II | ||
*Patient's on ARB's may have decreased response to Angiotensin II | *Patient's on ARB's may have decreased response to Angiotensin II | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Angiotensin II]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Revisión actual - 21:58 20 mar 2026
Administration
- Type: vasopressor
- Dosage Forms: Injection: 2.5 mg/mL and 5 mg/2 mL (2.5 mg/mL) in a vial
- Routes of Administration: IV
- Common Trade Names: GIAPREZA
Adult Dosing
Septic or Distributive Shock
- 20 nanograms (ng)/kg/min.
- Titrate as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed.
- Titrate as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed.
During the first 3 hours, the maximum dose should not exceed 80 ng/kg/min.
Maintenance dose should not exceed 40 ng/kg/min
Special Populations
Pregnancy Rating
- unkown
Lactation risk
- unknown
Renal Dosing
None
Hepatic Dosing
None
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Thrombosis (13%)
- DVT (4%)
- Thrombocytopenia (9%)
- Tachycardia (8.6%)
- Fungal infection (6.1%)
Common
Pharmacology
- Half-life: ~1 minute
- Metabolism: broken down by proteins in blood, RBC's, major organs
Mechanism of Action
- Synthetic human angiotensin II which is a peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure
- Increases Aldosterone
Comments
- Patient's on ACEi may have increased response to Angiotensin II
- Patient's on ARB's may have decreased response to Angiotensin II
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Vasopressors | 20 ng/kg/min, max 40-80 ng/kg/min | Salvage vasopressor | IV drip | Adult |